(E)-4-ethylcinnamic acid chloride | 120681-08-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-4-ethylcinnamic acid chloride
• 英文别名: (E)-4-ethylcinnamoyl chloride；(E)-3-(4-ethylphenyl)prop-2-enoyl chloride
• CAS: 120681-08-5
• 化学式: C₁₁H₁₁ClO
• 分子量: 194.661
• InChiKey: AXGUJMXDTRGASZ-BQYQJAHWSA-N

物化性质

• 沸点：
  292.0±9.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,8-双(三氟甲基)-4-羟基喹啉 、 (E)-4-ethylcinnamic acid chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Antifungal Exploration of Quinoline Derivatives against Phytopathogenic Fungi Inspired by Quinine Alkaloids

  摘要：

  DOI：

  10.1021/acs.jafc.1c05677
• 作为产物：
  描述：

  (E)-3-(4-乙基苯基)丙烯酸 在 氯化亚砜 作用下， 反应 3.0h， 生成 (E)-4-ethylcinnamic acid chloride
  参考文献：
  名称：

  Phenylalanine derivatives enhancing intestinal absorption of insulin in mice.

  摘要：

  研究了N-酰基-L-和D-苯丙氨酸衍生物对正常小鼠胰岛素肠道吸收的辅助效应。根据小鼠口服胰岛素和辅料联合给药后的血糖浓度和胰岛素水平，推测了N-酰基部分的化学结构性质与促吸收活性之间的相关性。N-酰基-苯丙氨酸衍生物对胰岛素肠道吸收具有辅效应的化学结构性质如下：1. 芳环存在，与酰基羰基相隔两个原子。2. 图2中的X或Y之一为氧，或者X-Y是双键。3. N-酰基部分具有较小的疏水取代基，如F、Cl或Me在Rα、Rβ、Rη位置，并且整个分子具有适当的亲水-疏水平衡。利用这些制剂增强胰岛素吸收，为口服胰岛素治疗提供了新的途径。

  DOI：

  10.1248/cpb.36.4426

文献信息

• [EN] RODENTICIDAL NORBORMIDE ANALOGUES<br/>[FR] ANALOGUES DE NORBORMIDE RODENTICIDE
  申请人：LANDCARE RES NEW ZEALAND LTD

  公开号：WO2013133726A1

  公开（公告）日：2013-09-12

  The present invention relates to norbormide analogues having rodenticidal activity; rodenticidal compositions comprising the analogues; uses of the analogues as rodenticides; uses of the analogues in the manufacture of rodenticidal compositions; and methods for controlling rodents using the compositions.

  本发明涉及具有杀鼠活性的诺波酰胺类似物；包括这些类似物的杀鼠组合物；将这些类似物用作杀鼠剂的用途；将这些类似物用于制造杀鼠组合物的用途；以及使用这些组合物控制啮齿动物的方法。
• Non-thiol Farnesyltransferase Inhibitors: Utilization of the Far Aryl Binding Site by 5-Cinnamoylaminobenzophenones
  作者：Andreas Mitsch、Pia Wißner、Markus Böhm、Katrin Silber、Gerhard Klebe、Isabel Sattler、Martin Schlitzer

  DOI：10.1002/ardp.200400871

  日期：2004.9

  We recently described two novel aryl binding sites of farnesyltransferase. In this study, the cinnamoyl residue was designed as an appropriate substituent for our benzophenone‐based AAX‐peptidomimetic compound capable of occupying the far aryl binding site.

  我们最近描述了法呢基转移酶的两个新的芳基结合位点。在这项研究中，肉桂酰基残基被设计为我们基于二苯甲酮的 AAX 肽模拟化合物的合适取代基，能够占据远芳基结合位点。
• Phenylalanine derivatives enhancing intestinal absorption of insulin in mice.
  作者：YUSUKE AMINO、KAZUHIRO KAWADA、KOJI TOI、IZUMI KUMASHIRO、KOJI FUKUSHIMA

  DOI：10.1248/cpb.36.4426

  日期：——

  The adjuvant effect of N-acyl-L-and D-phenylalanine derivatives on intestinal absorption of insulin was investigated in normal mice. The correlation between the chemical structural properties of the N-acyl moiety and the absorption-promoting activity was estimated from the glucose concentrations and the insulin levels in the blood of mice after oral combined administration of insulin and adjuvant. The chemical structural properties of N-acyl-phenylalanine derivatives necessary for adjuvant effect on intestinal absorption of insulin were as follows. 1. An aromatic ring is present, separated by two atoms from the acyl carbonyl group. 2. Either of X or Y is oxygen or X-Y is a double bond in Fig.2. 3. The N-acyl moiety has small hydrophobic substituents, such as F, Cl, or Me at Rα, Rβ, Rη and has an appropriate hydrophilic-hydrophobic balance of the overall molecule. The use of these agents to enhance insulin absorption offers the possibility of a new approach to oral insulin therapy.

  研究了N-酰基-L-和D-苯丙氨酸衍生物对正常小鼠胰岛素肠道吸收的辅助效应。根据小鼠口服胰岛素和辅料联合给药后的血糖浓度和胰岛素水平，推测了N-酰基部分的化学结构性质与促吸收活性之间的相关性。N-酰基-苯丙氨酸衍生物对胰岛素肠道吸收具有辅效应的化学结构性质如下：1. 芳环存在，与酰基羰基相隔两个原子。2. 图2中的X或Y之一为氧，或者X-Y是双键。3. N-酰基部分具有较小的疏水取代基，如F、Cl或Me在Rα、Rβ、Rη位置，并且整个分子具有适当的亲水-疏水平衡。利用这些制剂增强胰岛素吸收，为口服胰岛素治疗提供了新的途径。
• Benzimidazole cyclooxygenase-2 inhibitors
  申请人：——

  公开号：US20030013886A1

  公开（公告）日：2003-01-16

  This invention provides a compound of the following formula: 1 Or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X 1 and X 2 are independently selected from halo, C 1 -C 4 alkyl, hydroxy, C 1 -C 4 alkoxy, amino, C 1 -C 4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C 1 -C 4 alkyl)thio, (C 1 -C 4 alkyl)sulfinyl, (C 1 -C 4 alkyl)sulfonyl, aminosulfonyl, or the like; R 1 is selected from hydrogen,. straight or branched C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 8 cycloalkenyl, phenyl , heteroaryl and the like; R 2 and R 3 are independently selected from hydrogen, halo, C 1 -C 4 alkyl, phenyl and the like; or R 1 and R 2 can form, together with the carbon atom to which they are attached, a C 5 -C 7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.

  本发明提供以下式的化合物：1或其药学上可接受的盐，其中Ar是杂环芳基；X1和X2分别选自卤素，C1-C4烷基，羟基，C1-C4烷氧基，氨基，C1-C4酰基，羧基，氨基甲酰基，氰基，硝基，巯基，(C1-C4烷基)硫基，(C1-C4烷基)亚砜基，(C1-C4烷基)磺酰基，氨基磺酰基，或类似物；R1选自氢，直链或支链C1-C4烷基，C3-C8环烷基，C4-C8环烯基，苯基，杂环芳基等；R2和R3分别选自氢，卤素，C1-C4烷基，苯基等；或R1和R2可以与它们所连接的碳原子一起形成C5-C7环烷基环；m和n分别独立地为0、1、2或3。这些化合物和含有这些化合物的药物组合物在作为镇痛和抗炎药物方面是有用的。
• Benzimidazole cyclooxygenase-2 inhibitor
  申请人：Pfizer Inc

  公开号：US20040181062A1

  公开（公告）日：2004-09-16

  This invention provides a compound of the following formula: 1 or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X 1 and X 2 are independently selected from halo, C 1 -C 4 alkyl, hydroxy, C 1 -C 4 alkoxy, amino, C 1 -C 4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C 1 -C 4 alkyl)thio, (C 1 -C 4 alkyl)sulfinyl, (C 1 -C 4 alkyl)sulfonyl, aminosulfonyl, or the like; R 1 is selected from hydrogen, straight or branched C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 8 cycloalkenyl, phenyl, heteroaryl and the like; R 2 and R 3 are independently selected from hydrogen, halo, C 1 -C 4 alkyl, phenyl and the like; or R 1 and R 2 can form, together with the carbon atom to which they are attached, a C 5 -C 7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.

  这项发明提供了以下公式的化合物：1或其药学上可接受的盐，其中Ar是杂环芳基；X1和X2独立选择自卤素，C1-C4烷基，羟基，C1-C4烷氧基，氨基，C1-C4酰基，羧基，氨基甲酰基，氰基，硝基，巯基，（C1-C4烷基）硫醇基，（C1-C4烷基）亚砜基，（C1-C4烷基）磺酰基，氨基磺酰基等；R1选择自氢，直链或支链C1-C4烷基，C3-C8环烷基，C4-C8环烯基，苯基，杂环芳基等；R2和R3独立选择自氢，卤素，C1-C4烷基，苯基等；或者R1和R2可以与它们所附着的碳原子一起形成C5-C7环烷基环；m和n独立选择自0、1、2或3。这些化合物和含有这些化合物的药物组合物可用作镇痛剂和抗炎剂。